Mirabegron (formerly YM-178 trade name Myrbetriq) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder which leads to muscle relaxation and an increase in bladder capacity.
This page contains content from the copyrighted Wikipedia article "Mirabegron"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
